UEG and EAES Rapid Guideline: Systematic review, meta-analysis, GRADE assessment and evidence-informed European recommendations on TaTME for rectal cancer

Published by Marco Milone on Mar 10, 2022

Disclaimer

This clinical practice guideline has been developed under the auspice of the European Association for Endoscopic Surgery (EAES). It is intended to be used primarily by health professionals (e.g. surgeons, anaesthetists, physicians) and to assist in making informed clinical decisions on diagnostic measures and therapeutic management. It is also intended to inform individual practice of allied health professionals (e.g. surgical nurses, dieticians, physical rehabilitation therapists, psychologists); to inform strategic planning and resource management by health care authorities (e.g. regional and national authorities, health care institutions, hospital administration authorities); and to inform patients wishing to obtain an overview of the condition of interest and its management.
The use of recommendations contained herein must be informed by supporting evidence accompanying each recommendation and by research evidence that might not have been published by the time of writing the present document. Users must thus base their actions informed by newly published evidence at any given point in time.
The information in the guideline should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time the guideline is developed and when it is published or read. The guideline is not continually updated and may not reflect the most recent evidence. The guideline addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This guideline does not mandate any particular course of medical care. Further, the guideline is not intended to substitute the independent professional judgment of the treating provider, as the guideline does not necessarily account for individual variation among patients.
Even if evidence on a topic suggests a specific diagnostic and/or treatment action, users and especially health professionals may need to decide against the suggested or recommended action in view of circumstances related to patient values, preferences, co-morbidities and disease characteristics; available human, monetary and material resources; and healthcare infrastructures.
EAES provides this guideline on an “as is” basis, and makes no warranty, express or implied, regarding the guideline.

Sponsors

This project is funded and sponsored by United European Gastroenterology and the European Association for Endoscopic Surgery.

Contact

Abstract

This rapid guideline addresses questions on the use of TaTME in patients with rectal cancer.

Language

en

PICOS

PICO 40.1

Population
Patients with mid/low rectal cancer Malignant tumor of rectum 363351006, Malignant neoplasm of colon C18, ,
Intervention
TaTME Malignant tumor of rectum 363351006, Malignant neoplasm of colon C18, ,
Comparator
Lap TME Malignant tumor of rectum 363351006, Malignant neoplasm of colon C18, ,
Outcomes
Malignant tumor of rectum 363351006, Malignant neoplasm of colon C18, ,

PICO 40.2

Population
Patients with mid/low rectal cancer Malignant tumor of rectum 363351006,
Intervention
TaTME Malignant tumor of rectum 363351006,
Comparator
Robotic TME Malignant tumor of rectum 363351006,
Outcomes
Malignant tumor of rectum 363351006,